Swiss National Bank’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-117,542
| Closed | -$2.22M | – | 2590 |
|
|
2019
Q3 | $2.22M | Buy |
117,542
+4,400
| +4% | +$50.3K | ﹤0.01% | 1599 |
|
|
2019
Q2 | $1.33M | Hold |
113,142
| – | – | ﹤0.01% | 1957 |
|
|
2019
Q1 | $1.54M | Buy |
113,142
+3,500
| +3% | +$45.3K | ﹤0.01% | 1823 |
|
|
2018
Q4 | $1.12M | Hold |
109,642
| – | – | ﹤0.01% | 1936 |
|
|
2018
Q3 | $1.83M | Hold |
109,642
| – | – | ﹤0.01% | 1772 |
|
|
2018
Q2 | $1.73M | Hold |
109,642
| – | – | ﹤0.01% | 1792 |
|
|
2018
Q1 | $1.39M | Hold |
109,642
| – | – | ﹤0.01% | 1884 |
|
|
2017
Q4 | $1.25M | Buy |
109,642
+12,300
| +13% | +$137K | ﹤0.01% | 1951 |
|
|
2017
Q3 | $1.19M | Buy |
97,342
+31,000
| +47% | +$323K | ﹤0.01% | 1951 |
|
|
2017
Q2 | $760K | Hold |
66,342
| – | – | ﹤0.01% | 2217 |
|
|
2017
Q1 | $1.38M | Buy |
66,342
+1,700
| +3% | +$37.6K | ﹤0.01% | 1812 |
|
|
2016
Q4 | $1.34M | Hold |
64,642
| – | – | ﹤0.01% | 1836 |
|
|
2016
Q3 | $2.12M | Buy |
64,642
+1,100
| +2% | +$33.5K | ﹤0.01% | 1468 |
|
|
2016
Q2 | $1.59M | Buy |
63,542
+26,742
| +73% | +$724K | ﹤0.01% | 1668 |
|
|
2016
Q1 | $868K | Buy |
36,800
+8,600
| +30% | +$199K | ﹤0.01% | 1993 |
|
|
2015
Q4 | $931K | Hold |
28,200
| – | – | ﹤0.01% | 1872 |
|
|
2015
Q3 | $924K | Buy |
28,200
+3,900
| +16% | +$166K | ﹤0.01% | 1823 |
|
|
2015
Q2 | $1.29M | Buy |
+24,300
| New | +$884K | ﹤0.01% | 1624 |
|
Swiss National Bank's ALDR Position: Q4 2019 in Review
Swiss National Bank sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 117,542 shares — an estimated $2.22M sold.
Swiss National Bank first reported a position in ALDR in Q2 2015 and held it in 18 quarters. The position peaked at $2.22M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Swiss National Bank reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Swiss National Bank sold 117,542 Alder Biopharmaceuticals shares in Q4 2019, an estimated $2.22M.
- Swiss National Bank first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 18 quarters.
- Swiss National Bank's Alder Biopharmaceuticals position peaked at $2.22M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.